Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.560
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
4.560
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:30 PM EDT
Nuvation Bio Employees
Nuvation Bio had 298 employees as of December 31, 2025. The number of employees increased by 78 or 35.45% compared to the previous year.
Employees
298
Change (1Y)
78
Growth (1Y)
35.45%
Revenue / Employee
$211,081
Profits / Employee
-$686,668
Market Cap
1.59B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Intellia Therapeutics | 377 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Innoviva | 159 |
| AnaptysBio | 104 |
| AtaiBeckley | 99 |
| Rapport Therapeutics | 84 |
NUVB News
- 1 day ago - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - PRNewsWire
- 7 days ago - Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 - PRNewsWire
- 8 days ago - Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 - PRNewsWire
- 27 days ago - Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PRNewsWire
- 4 weeks ago - Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - PRNewsWire
- 5 weeks ago - NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 - PRNewsWire
- 6 weeks ago - Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026 - Transcripts